Connect Biopharma Holdings Limited (CNTB) vs Kalaris Therapeutics Inc (KLRS)
A side-by-side comparison of Connect Biopharma Holdings Limited and Kalaris Therapeutics Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CNTB
Connect Biopharma Holdings Limited
$0.91HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
KLRS
Kalaris Therapeutics Inc
$2.66HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CNTB vs KLRS
growth of $100 · dividends reinvested · last 6yCNTB -95.1% (-39.6%/yr)KLRS -100.0% (-75.7%/yr)CNTB compounded faster over this window
Log scale — wide-divergence pair
CNTB KLRS
CNTB vs KLRS: by the numbers
- •KLRS is the larger company ($58M vs $57M market cap).
- •Both run net losses; KLRS's is the smaller (0.00% vs -86687.50% net margin).
Metrics side by side
Valuation
| Metric | CNTB | KLRS |
|---|---|---|
| P/B ratio | 2.12 | 1.01 |
Profitability
| Metric | CNTB | KLRS |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -90740.62% | 0.00% |
| Net margin | -86687.50% | 0.00% |
| ROE | -132.16% | -76.75% |
| ROIC | -136.77% | -52.40% |
Growth (annualized)
| Metric | CNTB | KLRS |
|---|---|---|
| Total return CAGR (5Y) | -47.22% | -81.13% |
Frequently asked
- How have CNTB and KLRS total returns compared?
- Over the past 5 years, CNTB delivered -47.22% and KLRS delivered -81.13% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.